Network indirect comparison of 3 BRAF + MEK inhibitors for the treatment of advanced BRAF mutated melanoma.

F ConsoliM BersanelliG PeregoS GrisantiB MerelliA BerrutiFausto Petrelli

Published in: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2019)

This indirect adjusted meta-analysis suggests a similar efficacy and a slightly different safety profile, related to specific molecular properties of the three different BRAF and MEK inhibitors currently approved in the management of advanced MM.

Keyphrases

wild type
metastatic colorectal cancer
systematic review
pi k akt
meta analyses
combination therapy
skin cancer
network analysis
drug induced
clinical evaluation